Efficacy and safety of neratinib and capecitabine in HER2 positive metastatic breast cancer: a systematic review

被引：0
|
作者：
Mokalu, E. Wilhelmina [1 ]
Sabran, M. Zuhriansyah [1 ]
Yossy, P. [1 ]
Rubismo, K. Yogasvara [1 ]
Zebua, A. [1 ]
Albert, N. [1 ]
Hasan, J. Irisha Xenia [1 ]
Kurniawan, A. [2 ]
机构：
[1] Univ Pelita Harapan, Fac Med, Tangerang, Indonesia
[2] Univ Pelita Harapan, Dept Internal Med, Fac Med, Tangerang, Indonesia
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.07.472
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P90-6
引用
收藏
页码：S1393 / S1393
页数：1
相关论文
共 50 条
  • [21] Hormone receptor positive, HER2 negative metastatic breast cancer: A systematic review of the current treatment landscape
    Beith, Jane
    Burslem, Katie
    Bell, Richard
    Woodward, Natasha
    Mccarthy, Nicole
    De Boer, Richard
    Loi, Sherene
    Redfern, Andrew
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 3 - 18
  • [22] Efficacy and Safety of Neratinib (HKI-272) in Combination with Paclitaxel in Her2+Metastatic Breast Cancer
    Chow, L.
    Gupta, S.
    Hershman, D. L.
    Epstein, R.
    Bondarenko, I.
    Van, M-L Vo
    Freyman, A.
    Zhao, Y.
    Abbas, R.
    Awada, A.
    CANCER RESEARCH, 2010, 70
  • [23] Novel therapies for metastatic HER2 positive breast cancer
    Cossetti R.J.D.
    Gelmon K.A.
    Current Breast Cancer Reports, 2013, 5 (4) : 331 - 340
  • [24] Efficacy of HER2 inhibitors in metastatic breast cancer by discordance in HER2 amplification status between primary and metastatic breast cancer
    Van Raemdonck, E.
    Berteloot, P.
    Laenen, A.
    Han, S.
    Van Nieuwenhuysen, E.
    Salihi, R.
    Concin, N.
    Vergote, I.
    Floris, G.
    Wildiers, H.
    Punie, K.
    Neven, P.
    CANCER RESEARCH, 2019, 79 (04)
  • [25] The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis
    Petrelli, Fausto
    Ghidini, Michele
    Lonati, Veronica
    Tomasello, Gianluca
    Borgonovo, Karen
    Ghilardi, Mara
    Cabiddu, Mary
    Barni, Sandro
    EUROPEAN JOURNAL OF CANCER, 2017, 84 : 141 - 148
  • [26] Neratinib Plus Capecibine in Patients With HER2-Positive Metastatic Breast Cancer
    Mo, Dun-Chang
    Luo, Peng-Hui
    Huang, Jian-Feng
    Huang, Shang-Xiao
    Wang, Han-Lei
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03) : 252 - +
  • [27] Neratinib: An Option for HER2-Positive Metastatic Breast Cancer-Q&A
    O'Shaughnessy, Joyce
    O'Regan, Ruth
    Isaacs, Claudine
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 15 - 17
  • [28] Neratinib: Clinical Trial Data in HER2-Positive Metastatic Breast Cancer
    O'Shaughnessy, Joyce A.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 7 - +
  • [29] Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer
    Yuan, Yuan
    Lee, Jin Sun
    Yost, Susan E.
    Stiller, Tracey
    Blanchard, M. Suzette
    Padam, Simran
    Katheria, Vani
    Kim, Heeyoung
    Sun, Canlan
    Tang, Aileen
    Martinez, Norma
    Patel, Niki Dipesh
    Sedrak, Mina S.
    Waisman, James
    Li, Daneng
    Sanani, Shamel
    Presant, Cary A.
    Mortimer, Joanne
    JOURNAL OF GERIATRIC ONCOLOGY, 2021, 12 (05) : 752 - 758
  • [30] Tucatinib Plus Trastuzumab and Capecitabine for ERBB2 (HER2)-Positive Metastatic Breast Cancer With Brain Metastases
    Mo, Dun-Chang
    Luo, Peng-Hui
    Huang, Jian-Feng
    JAMA ONCOLOGY, 2023, 9 (07) : 1008 - 1009
12345